Letter comments re: Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A NCDB analysis

We have read with interest the seminal publication by Dr Aileen Deng and colleagues, which compared overall survival (OS) based on sequence and type of chemotherapy received in 18,470 patients who underwent surgery for early-stage (stage I or II) pancreatic adenocarcinoma between 2010 and 2014, identified from the National Cancer Database (NCDB) [1]. Five comparison matches – (1) NAT versus upfront resection (UR); (2) multi-agent neoadjuvant (MA NAT) versus single-agent adjuvant therapy (SA AT), single-agent neoadjuvant therapy (SA NAT), multi-agent adjuvant therapy (MA-AT); (3) MA NAT versus MA-AT; 4: NAT + AT versus NAT; 5: NAT + AT versus AT were construct ed using a minimum distance matching strategy.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research